Innovative therapeutics

Investors

BioMarin Named To Forbes List Of America's Best Mid-size Employers
Company Ranks 3rd Among Mid-Size Employers in Biotechnology
May 1, 2018

SAN RAFAEL, Calif., May 1, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that it has been ranked 51st overall among 500 companies on Forbes magazine's 2018 list of "America's Best Mid-size Employers," and third among companies in the biotechnology industry. For more than 20 years, BioMarin has been focused on making a big difference for small patient populations by rapidly developing first-in-class or best-in-class therapies to treat rare genetic diseases.

BioMarin Pharmaceutical logo (PRNewsfoto/BioMarin Pharmaceutical Inc.)

"Forbes seeks to discover which companies operating in the U.S. today are best at making their employees feel happy, inspired, and well-compensated," Forbes explained in presenting a list of 500 mid-size employers selected from about 2,000 companies.

This is the first year that BioMarin has received the distinction of being included on the Forbes list of  "America's Best Mid-size Employers," which recognizes the deep commitment of BioMarin employees to the rare disease communities they serve.  Forbes has also recognized BioMarin on its "Most Innovative Companies" list for the past four consecutive years where it has been ranked in the top 12 each year. 

"Being named by Forbes as a Best Employer is a source of pride for all of us at BioMarin.  This recognition combined with being named a top 20 company on Forbes Most Innovative Companies list over the last four years highlights important attributes that attract and engage employees, who share a commitment to each other and the rare disease patients we serve," said Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin. 

"Our people are the most valuable resources we have, and this honor from Forbes is a testament to BioMarin's commitment to creating and fostering a work environment where people can flourish while making a big difference in small patient populations," said Rich Ranieri, Executive Vice President, Human Resources.  "Individuals come to BioMarin to be scientific pioneers in rare disease, and they stay because they are making a big impact on the lives of patients and their families."

To view the complete list of Forbes winners, click here.

Methodology
Almost 30,000 employees at companies with at least 1,000 people were surveyed for the America's Best Employers List. The survey was conducted with global digital data collection partners who use innovative technology and proven sampling methodologies to facilitate a deep understanding of consumer opinions and behavior. Participation in the survey was voluntary, and respondents were recruited from thousands of sources to maximize reach and representation.

Besides more than 30 detailed questions about working conditions, the American employees were asked to determine, on a scale of zero to 10, how likely they were to recommend their employer to someone else. And further, how they feel about the other employers in their respective industries. The mix of respondents (gender, age, region, and ethnicity) in the sample represents American employees.

In total 1,000 employers have been awarded. Of those awarded 500 are large employers and 500 are mid-size employers.

About BioMarin
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases. The company's portfolio consists of six commercialized products and multiple clinical and pre-clinical product candidates. For additional information, please visit www.biomarin.com

BioMarin® is a registered trademark of BioMarin Pharmaceutical Inc. and its affiliates.

Contact:



Investors: 

Media:

Traci McCarty

Debra Charlesworth

BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.

(415) 455-7558 

(415) 455-7451

 

SOURCE BioMarin Pharmaceutical Inc.


BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: [email protected]

Global Medical Information

Contact Global Medical Information